We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-5.12%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$6.23B
AUM Growth
-$401M
Cap. Flow
+$712M
Cap. Flow %
11.42%
Top 10 Hldgs %
46.21%
Holding
101
New
19
Increased
9
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$193M
2
JBIO
Jade Biosciences
JBIO
+$189M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$104M
4
LENZ
LENZ Therapeutics
LENZ
+$67.1M
5
CNTB
Connect Biopharma Holdings
CNTB
+$66.7M

Top Sells

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$92.3M
2
NVAX icon
Novavax
NVAX
+$81M
3
IGMS
IGM Biosciences
IGMS
+$75.4M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$52.4M
5
TGTX icon
TG Therapeutics
TGTX
+$50.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
2 Financials 0.5%
3 Miscellaneous 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
26
Rhythm Pharmaceuticals
RYTM
$6.66B
$71.1M 1.14%
4,871,067
– –
CYT
27
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$69.5M 1.12%
+3,247,117
New +$60.8M
GHRS icon
28
GH Research
GHRS
$1.89B
$64.7M 1.04%
+2,978,955
New +$60.8M
OLMA icon
29
Olema Pharmaceuticals
OLMA
$856M
$60.2M 0.97%
2,150,404
– –
DYN icon
30
Dyne Therapeutics
DYN
$3.34B
$59M 0.95%
2,805,045
– –
PMVP icon
31
PMV Pharmaceuticals
PMVP
$72.7M
$58.4M 0.94%
1,710,265
– –
KALA icon
32
KALA BIO
KALA
$9.82M
$57.6M 0.93%
4,354
– –
CRIS icon
33
Curis
CRIS
$2.74M
$57.6M 0.92%
17,850
– –
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$56.4M 0.9%
2,200,000
– –
EWTX icon
35
Edgewise Therapeutics
EWTX
$4.74B
$55.7M 0.89%
2,613,623
– –
ORTX
36
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$54.1M 0.87%
1,231,521
– –
SPRY icon
37
ARS Pharmaceuticals
SPRY
$423M
$53.8M 0.86%
1,742,186
– –
VERV
38
DELISTED
Verve Therapeutics
VERV
$53M 0.85%
+880,284
New +$36.5M
CCCC icon
39
C4 Therapeutics
CCCC
$422M
$52.1M 0.84%
1,377,569
– –
WVE icon
40
Wave Life Sciences
WVE
$879M
$51.8M 0.83%
7,775,207
– –
TRIL
41
DELISTED
Trillium Therapeutics Inc.
TRIL
$51.3M 0.82%
5,290,481
– –
ACHL
42
DELISTED
Achilles Therapeutics
ACHL
$49.1M 0.79%
5,014,687
+3,625,799
+261% +$49.2M
CCXI
43
DELISTED
ChemoCentryx, Inc.
CCXI
$46.8M 0.75%
3,496,639
-60,171
-2% -$1.48M
KALV
44
DELISTED
KalVista Pharmaceuticals
KALV
$46.3M 0.74%
1,930,322
+1,580,322
+452% +$41.3M
ARDX icon
45
Ardelyx
ARDX
$878M
$46.1M 0.74%
6,077,294
– –
SLDB icon
46
Solid Biosciences
SLDB
$897M
$45.3M 0.73%
824,525
– –
DSGN icon
47
Design Therapeutics
DSGN
$765M
$43.5M 0.7%
2,186,636
– –
GERN icon
48
Geron
GERN
$842M
$42.5M 0.68%
30,126,299
– –
STSA
49
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$41.7M 0.67%
5,914,252
– –
LEGN icon
50
Legend Biotech
LEGN
$3.44B
$40.1M 0.64%
+977,503
New +$33.2M
1
2
3 4 5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, RA Capital Management held 101 positions worth $6.23B, down 6.1% from $6.63B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

RA Capital Management deployed $712M of net new capital in Q2 2021, opening 19 new positions and adding to 9 existing holdings. Its largest new stake was Janux Therapeutics: 8,670,644 shares worth $216M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Novavax, an estimated $81M trimmed.

  • RA Capital Management's largest Q2 2021 buy was Janux Therapeutics: 8,670,644 shares worth $216M.
  • RA Capital Management added most to Connect Biopharma Holdings in Q2 2021, an estimated $66.7M increase.
  • RA Capital Management's biggest Q2 2021 reduction was Novavax, cutting an estimated $81M.
  • RA Capital Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $92.3M.
  • RA Capital Management's ten largest holdings make up 46% of its $6.23B portfolio in Q2 2021.
  • RA Capital Management opened 19 new positions and closed 9 in Q2 2021.
  • RA Capital Management's portfolio value fell 6.1% quarter-over-quarter to $6.23B.

Based on RA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.